130 related articles for article (PubMed ID: 8639448)
1. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate.
Yee TT; Cohen BJ; Pasi KJ; Lee CA
Br J Haematol; 1996 May; 93(2):457-9. PubMed ID: 8639448
[TBL] [Abstract][Full Text] [Related]
2. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
[TBL] [Abstract][Full Text] [Related]
3. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates.
Lefrère JJ; Mariotti M; Thauvin M
Lancet; 1994 Jan; 343(8891):211-2. PubMed ID: 7904670
[TBL] [Abstract][Full Text] [Related]
4. [Transmission of parvovirus B19 by blood and blood components].
Schwarz TF
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():27-31. PubMed ID: 8000251
[TBL] [Abstract][Full Text] [Related]
5. Transfusion-transmitted disease.
Lee CA
Baillieres Clin Haematol; 1996 Jun; 9(2):369-94. PubMed ID: 8800511
[TBL] [Abstract][Full Text] [Related]
6. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.
Matsui H; Sugimoto M; Tsuji S; Shima M; Giddings J; Yoshioka A
J Pediatr Hematol Oncol; 1999; 21(1):74-6. PubMed ID: 10029819
[TBL] [Abstract][Full Text] [Related]
7. Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates?
Mosley JW
Transfusion; 1994 Sep; 34(9):744-6. PubMed ID: 8091460
[No Abstract] [Full Text] [Related]
8. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses.
Flores G; Juárez JC; Montoro JB; Tusell JM; Altisent C; Juste C; Jardí R
Haemophilia; 1995 Apr; 1(2):115-7. PubMed ID: 27214319
[TBL] [Abstract][Full Text] [Related]
9. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
[TBL] [Abstract][Full Text] [Related]
10. [Severe parvovirus B19 infection in an immunocompetent child with hemophilia A].
Coumau E; Peynet J; Harzic M; Béal G; Castaigne S; Leverger G; Foucaud P
Arch Pediatr; 1996 Jan; 3(1):35-9. PubMed ID: 8745824
[TBL] [Abstract][Full Text] [Related]
11. [Blood-transmitted viral infections among haemophiliacs in Tunisia].
Langar H; Triki H; Gouider E; Bahri O; Djebbi A; Sadraoui A; Hafsia A; Hafsia R
Transfus Clin Biol; 2005 Oct; 12(4):301-5. PubMed ID: 16099190
[TBL] [Abstract][Full Text] [Related]
12. Use of digoxigenin-labelled probes for the detection of B19 parvovirus DNA in batches of blood products.
Lefrère JJ; Mariotti M
Cell Mol Biol (Noisy-le-grand); 1995 Nov; 41(7):985-8. PubMed ID: 8595378
[TBL] [Abstract][Full Text] [Related]
13. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs.
Grosse-Bley A; Eis-Hübinger AM; Kaiser R; Oldenburg J; Brackmann HH; Schwarz TF; Schneweis KE
Thromb Haemost; 1994 Oct; 72(4):503-7. PubMed ID: 7878623
[TBL] [Abstract][Full Text] [Related]
14. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia.
Yee TT; Lee CA; Pasi KJ
Lancet; 1995 Mar; 345(8952):794-5. PubMed ID: 7605434
[No Abstract] [Full Text] [Related]
15. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction.
Zakrzewska K; Azzi A; Patou G; Morfini M; Rafanelli D; Pattison JR
Br J Haematol; 1992 Jul; 81(3):407-12. PubMed ID: 1390215
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of human parvovirus B19 DNA contamination of factor VIII products.
Matsunaga Y
Dev Biol Stand; 1996; 88():217. PubMed ID: 9119140
[No Abstract] [Full Text] [Related]
18. Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools.
Rollag H; Patou G; Pattison JR; Degré M; Evensen SA; Fröland SS; Glomstein A
Scand J Infect Dis; 1991; 23(6):675-9. PubMed ID: 1815327
[TBL] [Abstract][Full Text] [Related]
19. Heat sensitivity of human parvovirus B19.
Yunoki M; Tsujikawa M; Urayama T; Sasaki Y; Morita M; Tanaka H; Hattori S; Takechi K; Ikuta K
Vox Sang; 2003 Apr; 84(3):164-9. PubMed ID: 12670364
[TBL] [Abstract][Full Text] [Related]
20. Eliminating parvovirus B19 from blood products.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M
Lancet; 1994 Mar; 343(8900):798. PubMed ID: 7907759
[No Abstract] [Full Text] [Related]
[Next] [New Search]
